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Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver
disease in developed countries. An in vitro NAFLD model would permit
mechanistic studies and enable high-throughput therapeutic screening.
While hepatic cancer-derived cell lines are a convenient, renewable resource,
their genomic, epigenomic and functional alterations mean their utility in
NAFLD modelling is unclear. Additionally, the epigenetic mark 5-hydroxy-
methylcytosine (5hmC), a cell lineage identifier, is rapidly lost during cell
culture, alongside expression of the Ten-eleven-translocation (TET) methylcy-
tosine dioxygenase enzymes, restricting meaningful epigenetic analysis.
Hepatocyte-like cells (HLCs) derived from human embryonic stem cells can
provide a non-neoplastic, renewable model for liver research. Here, we have
developed a model of NAFLD using HLCs exposed to lactate, pyruvate
and octanoic acid (LPO) that bear all the hallmarks, including 5hmC profiles,
of liver functionality. We exposed HLCs to LPO for 48 h to induce lipid
accumulation. We characterized the transcriptome using RNA-seq, the meta-
bolome using ultra-performance liquid chromatography-mass spectrometry
and the epigenome using 5-hydroxymethylation DNA immunoprecipitation
(hmeDIP) sequencing. LPO exposure induced an NAFLD phenotype in
HLCs with transcriptional and metabolomic dysregulation consistent with
those present in human NAFLD. HLCs maintain expression of the TET
enzymes and have a liver-like epigenome. LPO exposure-induced 5hmC
enrichment at lipid synthesis and transport genes. HLCs treated with LPO
recapitulate the transcriptional and metabolic dysregulation seen in NAFLD
and additionally retain TET expression and 5hmC. This in vitro model of
NAFLD will be useful for future mechanistic and therapeutic studies.
This article is part of the theme issue ‘Designer human tissue: coming to
a lab near you’.1. Introduction
Non-alcoholic fatty liver disease (NAFLD) now affects around 25–33% of the
population and up to 75% of obese individuals in developed countries [1,2].
NAFLD encompasses a spectrum of liver disease and while simple steatosis
is considered relatively benign, it can progress to non-alcoholic steatohepatitis
(NASH), fibrosis and cirrhosis, and approximately 25% of those with cirrhosis
will develop hepatocellular carcinoma (HCC) [3,4]. Progression is highly
variable between individuals, with only a minority of individuals reaching
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inter-individual variability, coupled with a lack of under-
standing of the underlying mechanisms, has limited the
development of effective therapeutic interventions.
Studies in whole liver may be confounded by shifting cell
populations, and therefore the possibility of recapitulation of
multiple facets of human NAFLD in a single cell-type in vitro
would be a key advance, permitting the dissection of disease
processes in mechanistic studies and enabling high-throughput
screening for new medicines. Exposure of cancer cell lines to
saturated (typically palmitate) or unsaturated (typically
oleate) long chain fatty acids results in steatosis accompanied
by upregulation of cytokines, interruption of insulin signalling,
increased reactive oxygen stress and apoptosis signalling [6–9].
However, while hepatic cancer-derived cell lines are a con-
venient, renewable resource, they have many genomic and
functional alterations so that their utility in modelling diseases
of overnutrition is unclear [10,11]. Primary hepatocytes isolated
from human tissue have also been employed to model disease
and predict drug toxicity, however, purification is technically
challenging and isolated cells rapidly lose phenotype in cell cul-
ture [12]. Furthermore, the gene expression changes that occur
with adaptation to culture resemble alterations present in
liver disease and may additionally be influenced by the
donor’s hepatic phenotype and pharmacological history [13].
The renewable, pluripotent nature of embryonic stem cells
(ESCs) presents an opportunity for human differentiated
tissue to be reproducibly generated in vitro for the investigation
of human disease processes. Exposure of ESCs to a refined
regime of chemical and biological growth stimuli over a three
to four week period allows robust, scalable generation of hep-
atocyte-like cells (HLCs) that exhibit a similar morphology,
function and transcriptome to human hepatocytes [13,14]. As
a consequence, HLCs have been used extensively in mechanis-
tic studies of drug-induced liver injury, hepatitis viral
replication, fetal xenobiotic exposure and the characterization
of inherited disorders of lipid metabolism [15–18].
Recent studies in human liver biopsy specimens and in
animal models suggest that epigenetic dysregulation could
play a role in NAFLD pathogenesis and progression [19–21].
Our studies suggest that the cytosine modification 5-hydroxy-
methylcytosine (5hmC) may be useful as a biomarker of both
normal and abnormal liver physiology [22,23]. However,
5hmC is rapidly lost during somatic cell adaptation to culture
and in all tested hepatocyte cell lines [24,25], making it difficult
to undertake meaningful epigenetic analyses (particularly
5hmC) in cultured cell line models. Here, we show that HLCs
derived from human ESCs retain the ability to form 5hmC, pro-
viding a non-neoplastic and renewable source of human cells
for liver research. Additionally, exposure of HLCs to a nutrient
cocktail of lactate, pyruvate and octanoic acid produces a robust
NAFLD-like phenotype in vitro.We believe thismodelwill be of
importance for further mechanistic studies of NAFLD on
defined genetic backgrounds.2. Material and methods
(a) Embryonic stem cell derived hepatocyte
differentiation and LPO treatment
Female H9 ESCs were differentiated into HLCs as previously
described [14]. At day 20 of differentiation, cells were exposedto sodium L-lactate (L), sodium pyruvate (P) and octanoic acid
(O) (all Sigma, Gillingham, UK) at low (L : P : O 10 mM : 1 mM :
2 mM) or high dose (L : P : O: 20 mM : 2 mM : 4 mM) for 48 or
96 h to determine optimal conditions for further study. The auto-
mated high-throughput system for HLC differentiation, staining
and objective image analysis is depicted in figure 1a; for detailed
methods, see the electronic supplementary material.
(b) Transcriptome profiling
RNAwas extracted andDNase treated usingQiazol, DNaseI and an
RNeasyMinikit (Qiagen, Manchester, UK). RNA labelling was per-
formed on 500 ng RNA using the Illumina Total Prep RNA
Amplification Kit (Life Technologies. Paisley, UK). Hybridization
of biotinylated RNA to Illumina HT-12 beadchip arrays (control
n ¼ 4, LPO treated n ¼ 6) with Illumina Whole Genome Gene
Expression Direct Hybridization Assay (WGGX kit, Illumina, Cam-
bridge, UK) was performed at the University of Edinburgh
Genomics Core (Western General Hospital, Edinburgh, UK). Ima-
ging was performed and analysed using the Illumina HiScan
platform and genotypes called automatically using GENOMESTUDIO
ANALYSIs software version 2011.1. Background subtraction, quartile
normalization and differential expression were performed using R
version3.2withLumiandLimmapackage, respectively.Geneontol-
ogy was performed using GOstats and KEGG pathway analysis
using Pathview (www.Bioconductor.org). Unsupervised clustering
was performed using Euclidean distance. Where multiple probes
mapped to the same gene, the median was used. Data have been
uploaded to EBI-Array Express, accession number E-MTAB-6227.
For validation, 800 ng mRNA were reverse transcribed using
the High Capacity cDNA Reverse Transcriptase Kit (Life Technol-
ogies, Paisley, UK). Quantitative real-time PCR validation was
performed using the Roche Universal Probe Library (Roche, Bur-
gess Hill, UK) or Taqman PCR assay (Life Technologies, Paisley,
UK) on the Roche Lightcycler 480 (Roche, Burgess Hill, UK) and
normalized to endogenous controls as indicated. Primers are in
the electronic supplementary material, table S1a.
(c) Metabolome profiling
Metabolome profiling on cell media and HLCs was undertaken
using ultra-performance liquid chromatography-mass spec-
trometry (UPLC-MS) using a Thermo Scientific Ultimate 3000
UPLC system coupled to an electrospray Q Exactive Focus mass
spectrometer. A hydrophilic interaction liquid chromatography
(HILIC) assay to investigate water-soluble metabolites and a C18
reversed phase method to investigate lipid metabolites were
applied. Univariate and multivariate data analyses were per-
formed in METABOANALYST 3.0 [26], including principal
components analysis (PCA), Mann Whitney U-tests or Kruskal–
Wallis tests to identify metabolites demonstrating a statistically
significant change in relative concentrations between two or
three biological classes. Fold changes were calculated by division
of the mean peak response for one biological class by the mean
peak response of the second biological class. For detailedmethods,
see the electronic supplementary material.
(d) 5hmC profiling
For slot blotting, serial dilutions of extracted DNA were blotted
onto Hybond Nþ nitrocellulose membrane (Amersham, Buckin-
ghamshire, UK) using a slot blot manifold (HSI, GE Healthcare,
Buckinghamshire UK), washed in 2xSSC buffer and dried over-
night. Membrane was then probed with 1 : 10 000 anti 5hmC
antibody (Active Motif, cat:39769) for 1 h at room temperature fol-
lowed by goat anti-rabbit IRDye 800CW (1 : 10 000) for 1 h at room
temperature and subsequent imaging on the Li-cor Odyssey infra-
red imaging system (both Li-cor, Cambridge, UK). DNA loading
was confirmed by staining with 0.02% methylene blue in 0.3 M
sodium acetate (pH 5.2) and destaining with ddH2O.
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20 mm
20 mm
LPO
matrix coating
and cell seeding
MultidropTM Combi
Reagent Dispenser 
ViaFlowTM
96/384
BioTeKTM
405 LS
OperettaTM HCS
PerkinElmer
cell feeding and
compound addition
cell fixation
and staining
imaging and multi-
parametric analysis
(a)
(b)
Figure 1. Incubation of HLCs with LPO at low or high dose for 48 or 96 h induces steatosis, respectively. (a) Experimental pathway for automated high-throughput cell
differentiation, cell staining and image analysis. (b) Fluorescence microscopy demonstrating BoDIPY staining of neutral lipid vacuoles within HLC following exposure to
LPO. (c) LPO induces a dose- and time-dependent increase in lipid vacuoles in HLCs. (d ) Exposure to LPO increases mitochondrial stress in a dose-dependent manner at
48 and 96 h. (e) LPO treatment does not affect cell functionality as determined by a CYP3A activity luciferase assay. CYP3A activity data are reported as relative light
units (RLU) normalized to protein content. ( f ) 96 h high-dose LPO increases apoptosis as determined by ATP production assay. Data are reported as RLU normalized to
protein content. (g) qPCR of mRNA levels of genes relevant to human NAFLD in control (Con, blue) versus 48 h LPO-treated (red) HLCs. Data are expressed relative to
the mean of control genes PPIA/B2M and were analysed by one-way ANOVA with Bonferroni correction. The minimum number of biological replicates is shown for each
experiment. *p, 0.05, **p, 0.01, ***p , 0.001, n.s. ¼ non-significant.
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and libraries sequenced on an Ion Torrent semiconductor
sequencer using the Ion PITM Hi-QTM Sequencing Kit and an
Ion PITM Chip Kit v3 (Thermo Fisher Scientific, Paisley, UK) to
a depth of approximately 30 million reads (see the electronic sup-
plementary material). Raw sequencing data were quality
controlled, filtered and aligned using Ion Torrent suite software
(Life Technologies, Paisley, UK) and then normalized to total
reads in R using bespoke scripts. Relative 5hmC levels per
150 bp window were determined using the ‘sliding windows’
function on the Galaxy server. Genomic annotation data for
human (hg19) analyses were downloaded from the University
of California Santa Cruz Genome Bioinformatics Resource.
Further details on hmeDIP bioinformatic processing can be
found in Thomson et al. [27]. Raw and processed data files are
available for download from the GEO repository accession
number GSE109139.
(e) Statistics
Prism GraphPad software (GraphPad Software Inc.) was used for
analysis of qPCR and cell culture variables. Data were routinelyanalysed for outliers and normality of distribution. Non-para-
metric data or data with significant outliers were log10
transformed. If data remained non-parametric, a non-parametric
test was used as indicated. Data point and bar graphs are shown
as mean+ s.e.m.3. Results
(a) Exposure of hepatocyte-like cells to lactate, pyruvate
and octanoate leads to steatosis and upregulation of
genes implicated in non-alcoholic fatty liver disease
pathogenesis
Human embryonic stem cells were differentiated to HLCs
using a semi automated system (figure 1a). At day 21,
HLCs formed a stable sheet of cells in a two-dimensions exhi-
biting polygonal morphology and cytoplasmic lipid droplets
(electronic supplementary material, figure S1a). During
differentiation, cells displayed a reduction in the
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Figure 1. (Continued.)
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(POU5F1) and Nanog homeobox (NANOG) with a concur-
rent increase in the hepatocyte-specific markers ALB and
hepatocyte nuclear factor 4 alpha (HNF4a) (electronic sup-
plementary material, figure S1b). At day 21, CYP1A2 and
CYP3A4 activity and secreted human albumin were evident
and consistent with previous reports [28,29] (electronic
supplementary material, figure S1c,d).
HLC LPO exposure induced a dose- and time-depen-
dent increase in lipid vacuole generation (figure 1b,c). LPO
exposure increased mitochondrial stress in a dose-dependent
manner at both 48 and 96 h of exposure as determined by an
increase in mitochondrial inner membrane potential allowinguptake of MitoTracker Deep Red dye (https://www.nature.
com/protocolexchange/protocols/3673#/equipment
figure 1d ). While LPO treatment did not affect cell functional-
ity as determined by CYP3A assay (figure 1e), high-dose LPO
over a longer duration increased apoptosis (figure 1f ). Thus,
to avoid studying secondary effects associated with cell
death, we opted for the lowest dose of LPO treatment for
48 h in all further analyses. qPCR analysis showed that LPO
exposure consistently stimulated the expression of multiple
putatively causal genes in NAFLD pathological processes,
including: fatty acid synthesis (ACACA, LXR, SREB1c), gluco-
neogenesis (PCK, G6PD) and lipid vesicular transport proteins
Perilipin 1 and 2 (PLIN1, PLIN2) (figure 1g).
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Figure 2. LPO-treated HLCs show transcriptional derangement. (a) Principal
component (PC) analysis of transcriptome from microarray studies following
48 h low-dose LPO exposure shows clustering of control (CON) and LPO-trea-
ted HLCs. (b) Transcriptome analysis volcano plot of mRNA expression
following LPO treatment. PLIN2, CIDEC, APOA4, AKR1C2 and AKR1C4 are
highly induced. Blue/red colours indicate 1.5-fold down- and upregulated
genes, adjusted p-value , 0.05. n ¼ 4 control and n ¼ 6 LPO.
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induces transcriptional dysregulation
We examined changes in transcription following 48 h LPO
exposure using the Illumina HT-12 beadchip microarray (Illu-
mina, San Diego, USA). PCA demonstrated clear separation
between treated and control populations (figure 2a). 48 h LPO
treatment resulted in the dysregulation of 2618 transcripts
(adjusted p-value, 0.05, Benjamini Hochberg false discovery
rate (FDR)), with upregulation of 1309 transcripts correspond-
ing to 1083 genes and downregulation of 1309 transcripts
mapping to 980 genes (greater than 10% transcriptional
change, Benjamini–Hochberg adjusted p-value 0.05; figure 2b
and electronic supplementary material, table S2). The magni-
tude of change is consistent with a number of human datasets
[20,30]. GO terms with the greatest enrichment in upregulated
transcripts included ‘GO:0044255’ ‘cellular lipid metabolic pro-
cess’, ‘GO:0090208’ ‘positive regulation of triglyceride
metabolic process’ and ‘GO:1901617’ ‘organic hydroxyl com-
pound biosynthetic process’ (electronic supplementarymaterial, figure S2a). A specific cluster of five genes were
induced to a particularly high degree of significance: the lipid
vesicle transport proteins Cell Death-Inducing DFFA-Like
Effector C (CIDEC), PLIN2, Apolipoprotein A4 (APOA4) and
the steroid hormone synthesis enzymes aldo-keto reductase
family 1, members C2, C4 (electronic supplementary material,
table S2).(c) Lactate, pyruvate and octanoic acid-induced
transcriptional and metabolic dysregulation is
consistent with mitochondrial dysfunction
We undertook metabolomic profiling in cells and media
following 48 h of LPO exposure using UPLC-MS. PCA
demonstrated clear separation between treated and control
populations (electronic supplementary material, figure
S3a,b). Mitochondrial dysfunction is a central feature of
NAFLD and the degree of dysfunction may be important in
determining the risk of progression from steatosis to NASH
[31]. Mitochondrial oxidative function encompasses many
processes, including tricarboxylic acid (TCA) cycle metab-
olism, b-oxidation, ketogenesis, respiratory chain activity
and ATP synthesis. In agreement with previous studies in
mice and human liver tissue [32,33], LPO exposure induced
significant TCA cycle dysregulation with altered expression
of a number of enzymes, including downregulation of
isocitrate dehydrogenase type 1 and 2 (IDH1 and 2) and
malate dehydrogenase type 1 (MDH1); and upregulation of
IDH3A, alpha-ketoglutarate dehydrogenase (OGDH) and
succinate dehydrogenase subunit A (SDHA) (electronic sup-
plementary material, figure S4a; table 1). We also observed
an increase in the metabolite oxalosuccinate, an intermediate
formed during the oxidative carboxylation of isocitrate to
alpha-ketoglutarate (electronic supplementary material,
figure S4a).
Breakdown of free fatty acids in liver involves b-oxi-
dation. Initial transport of unmodified long-chain fatty
acids through the mitochondrial membrane requires the
addition of carnitine by carnitine palmitoyl transferase 1
(CPT1), generating acyl carnitine species that are shuttled
into mitochondria by carnitine–acylcarnitine translocase.
Consistent with previous data [31], LPO-induced steatosis
was associated with activation of the b-oxidation transcrip-
tional pathway (electronic supplementary material, figure
S4b), with upregulation of long-chain-fatty acid-CoA ligase
1 (ACSL1), CPT1A, acyl coenzyme A dehydrogenase
(ACADM), very long-chain-specific acyl-CoA dehydrogenase
(ACADVL), and acetyl CoA acetyltransferase (ACAT1)
(electronic supplementary material, figure S4b). Defective
b-oxidation in NAFLD results in the accumulation of acyl car-
nitines and diacylglycerols [31], and in support of this we
observed substantial dysregulation of carnitine and acyl car-
nitine metabolites and glycerol species in cells and media
with LPO (figure 3a). Further, we observed marked altera-
tions in fatty acids, oxidized fatty acids and acyl glycine
species in LPO-treated cells and media (figure 3b). Defective
oxidative phosphorylation is also feature of NAFLD [31]
and we identified altered expression of transcripts involved
in all five of the mitochondrial complexes in LPO-treated
HLCs (table 1).
When b-oxidation is saturated/dysfunctional, surplus
fatty acids can be degraded through microsomal v-oxidation,
Table 1. Microarray analysis showing dysregulated transcripts in KEGG
pathways relevant to energy metabolism. Adj p-value ¼ adjusted p-value
(Benjamini–Hochberg correction).
KEGG pathway
gene
name log2FC
Adj p-
value
TCA cycle
hsa00020
IDH2 20.285 0.004
IDH3A 0.271 0.017
MDH1 20.192 0.025
OGDHL 0.360 0.001
SDHA 0.236 0.045
PCK1 0.635 0.007
fatty acid
degradation
hsa00071
ACSL1 0.459 0.007
CPT1A 0.281 0.001
ACADM 0.324 0.009
ACADVL 0.727 0.000
ACAT1 0.213 0.008
ADH1A 20.305 0.008
ALDH2 20.274 0.026
CYP4A11 0.814 0.008
oxidative
phosphorylation
hsa00190
NDUFB3 20.213 0.023
SDHC 20.252 0.031
SDHA 0.236 0.045
UQCRC1 0.226 0.019
ATP5J2 20.225 0.013
ATP5I 20.310 0.005
ATP6V0E2 0.308 0.005
ATP6V0D1 20.206 0.018
COX11 0.173 0.031
glycolysis/
gluconeogenesis
hsa00010
GLYCTK 20.454 0.004
AKR1A1 20.170 0.040
AKR1B10 1.139 0.000
PLPP2 0.385 0.006
CEL 20.319 0.014
NAFLD
hsa04932
LEP 20.793 0.001
CXCL8 0.772 0.043
CDC42 20.500 0.001
IRS2 0.485 0.001
CDC42 20.463 0.000
JUN 0.427 0.009
PIK3R1 20.349 0.003
ADIPOR2 0.292 0.001
AKT1 20.193 0.017
ERN1 0.180 0.038
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tively inefficient process increases cellular oxidative stress, a
key pathological mechanism in NAFLD progression.
LPO treatment was associated with activation of v-oxidation,
with upregulation of cytochrome P450 4A11 (CYP4a11)
(table 1) and accumulation of hydroxylated fatty acids incells and media (figure 3c). An alternative method of fatty
acid clearance involves the synthesis and sequestration of tri-
glycerides within lipid vesicles, the primary histological
finding in hepatic steatosis. Our findings of an LPO-induced
increase in glycerol-3-phosphate within cell media with
induction of phospholipid phosphatase 2 (PLPP2) and
suppression of the lipolytic enzyme carboxyl ester lipase
(CEL) support an increase in triglyceride synthesis in LPO--
treated HLCs (table 1). In addition to this, upregulation of
the lipid vesicle transport proteins PLIN1, PLIN2 (figure 1g)
and CIDEC and the structural lipoprotein APOA4 (figure 2b)
are reflected in the increase in lipid vacuoles with LPO
exposure.
(d) Other aspects of lactate, pyruvate and octanoic acid-
induced transcriptional and metabolic dysregulation
are consistent with non-alcoholic fatty liver disease
LPO treatment was associated with increased expression of
cytosolic phosphoenolpyruvate carboxykinase (PCK1;
table 1; electronic supplementary material, table S2), the
rate-limiting enzyme in gluconeogenesis and an important
regulator of TCA cycle activity. An increase in gluconeogen-
esis in LPO-exposed HLCs was supported by increased
phosphoenolpyruvate and glucose in cell media (table 2).
PCK1 may be an important therapeutic target because knock-
ing down PCK1 can prevent oxidative stress and
inflammation in mice on a high-fat diet [33]. Examination
of the KEGG pathway for NAFLD (hsa04932) demonstrated
transcriptional dysregulation of mediators of insulin resist-
ance (IRS2, P1K3R1, AKT1), steatohepatitis ( JUN, ERN1)
and neutrophil infiltration and inflammation (CXCL8)
(table 1).
(e) Hepatocyte-like cells maintain 5hmC and TET
enzyme expression in culture
Global epigenetic DNA modification levels and patterns are
frequently altered in cultured cells, particularly 5hmC,
which is vastly reduced genome-wide [24]. To test if our
system maintained a normal 5hmC landscape, we carried
out an antibody-based quantitative analysis of 5hmC in
HLCs and compared these to ESCs and HepG2 cells. HLCs
retain 5hmC levels at equivalent levels to mouse liver,
which is much higher than the minimal level observed in
HepG2 cells (figure 4a). Additionally, although mammalian
cell culture is associated with loss of Ten-eleven-translocation
(TET) enzyme expression [24], the expression of all three TET
isoforms is maintained in HLCs (figure 4b). TET1 is highly
expressed in ESCs and plays a critical role in the maintenance
of pluripotency [34] and consistent with this, TET1 mRNA
expression is downregulated at the later stages of the hepatic
differentiation protocol. TET2 is the dominant TET isoform
expressed in liver and expression was appropriately
increased during differentiation [35]. In order to validate
that HLCs have a liver-like hydroxymethylome and have
transitioned from an ESC state, we performed hmeDIP-
sequencing (hmeDIP-seq) on HLCs and compared profiles
with published datasets for 5hmC in human liver and
human ESCs [36,37]. We additionally performed hmeDIP-
seq on human kidney to assess tissue-specificity. Accord-
ingly, we observed high levels of 5hmC across key liver
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Figure 3. LPO treatment of HLCs induces dysfunction of oxidative phosphorylation. (a) Metabolomics analysis demonstrating that LPO induces a reduction in intra-
cellular acylcarnitines and dysregulation of acyl carnitine species (log2FC versus control, FDR , 0.01). (b) LPO treatment induced a reduction in native fatty acid
species in media (hatched bars) and cell (open bars) and (c) an accumulation of v oxidation products.
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liver datasets, while low levels of 5hmC were observed
over ESC and kidney 5hmC-enriched loci, e.g. the HoxA clus-
ter (electronic supplementary material, figure S5a,b). In both
human ESCs and liver, high levels of 5hmC are present at
transcription start site (TSS), distal promoter and proximal
gene body regions [38,39] and bioinformatic analysis of
5hmC datasets in HLCs showed a similar 5hmC profile
(figure 4c). As in previous studies, 5hmC patterns followed
transcriptional states, with highly transcribed genes contain-
ing more gene body 5hmC than lowly transcribed genes
[40] (figure 4c). Thus, 5hmC profiles are consistent with a
liver-like epigenome, supporting the utility of this cell line
for the study of human metabolic liver disease. We also pro-
filed 5hmC in LPO-treated and control HLCs using hmeDIP-
seq. Sliding window analysis showed no global change in
5hmC in LPO-exposed HLCs (figure 4d ), although we
observed some 5hmC enrichment within bodies of inducedgenes involved in lipid synthesis and transport (electronic
supplementary material, figure S6). Such changes allowed
for stratification by treatment (figure 4e) and highlight the
utility of combined transcriptomic and epigenetic profiling
to investigate molecular mechanisms.4. Discussion
NAFLD is strongly associated with obesity, insulin resistance
(IR), type 2 diabetes (T2DM) and cardiovascular disease [1]
and the increasing prevalence of these disorders is a substan-
tial public health burden. Indeed, NAFLD is an early
predictor of, and important determinant for, the development
of T2DM and the metabolic syndrome [41]. While the use of
rodent models of NAFLD to explore mechanisms and test
therapies is common, lipid metabolism in mice and humans
differs so that the applicability of mouse models to human
Table 2. Metabolite analysis: metabolites from media and cells showing differences between control and LPO-treated HLCs. FDR ¼ false discovery rate
correction for multiple testing.
metabolites sample KEGG pathway/compound group fold change FDR
1H-indole-3-carboxaldehyde cells aromatic metabolites 0.264 0.001
N’-formylkynurenine 0.116 0.000
butyrylcarnitine carnitine and acyl carnitine
metabolism
0.221 0.001
octanoylcarnitine 0.066 0.000
propionylcarnitine 3.145 0.050
octadecenol fatty acids and oxidized fatty acids 0.161 0.045
arginine media arginine metabolism 1.221 0.007
argininosuccinic acid 1.523 0.000
1H-indole-3-acetamide aromatic metabolite metabolism 1.096 0.008
1H-indole-3-carboxaldehyde 1.252 0.001
lactic acid 0.517 0.000
5-hydroxy-L-tryptophan 0.684 0.000
5-hydroxy-N-formylkynurenine 0.777 0.001
5-hydroxyindoleacetic acid 1.888 0.000
dihydroxyindole 0.833 0.004
formyl-5-hydroxykynurenamine 1.185 0.006
hydroxyphenylacetylglycine 1.803 0.000
indole 0.670 0.000
N’-formylkynurenine 36.59 0.000
phenylethylamine 0.006 0.000
tryptophan 1.683 0.001
butyrylcarnitine carnitine and acyl carnitine
metabolism
1.450 0.000
carnitine 1.139 0.001
hydroxy-hexadecenoylcarnitine 3.116 0.005
hydroxy-tetradecadiencarnitine 2.684 0.000
hydroxy-tetradecenoylcarnitine 5.062 0.001
octanoylcarnitine 0.060 0.000
propionylcarnitine 23.13 0.000
thiocysteine cysteine and methionine metabolism 5.485 0.001
dihydroxy-oxo-octadecenoic acid fatty acid and oxidized fatty acids 0.566 0.001
hydroxy-octadienoic acid 1.148 0.005
hydroxydecanoic acid 0.428 0.001
hydroxydodecanoic acid 295.9 0.003
hydroxyhexadecanoic acid media 1.498 0.006
hydroxynonanoic acid 1.481 0.000
octadecenol 0.403 0.006
octenedioic acid 0.780 0.001
glucose glycolysis/gluconeogenesis
hsa00010
1.179 0.000
glycerol-3-phosphate 37.34 0.001
glyceric acid glycolysis 0.644 0.003
lactic acid 0.577 0.000
phosphoenolpyruvic acid 1.474 0.004
phosphoglyceric acid 1.416 0.000
imidazolepropionic acid histidine metabolism 86.98 0.000
imidazole-4-acetaldehyde 0.004 0.000
(Continued.)
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Table 2. (Continued.)
metabolites sample KEGG pathway/compound group fold change FDR
7-methylguanosine purine and pyrimidine metabolism 56.27 0.000
cytidine 0.587 0.004
deoxycytidine 0.438 0.004
dihydroxypurine 0.606 0.000
glutamine TCA cycle and oxidative
phosphorylation
1.298 0.003
oxalosuccinic acid 1.325 0.002
2-methyl-1-hydroxypropyl-ThPP valine, leucine and isoleucine
metabolism
1.162 0.001
isopropylmaleate 2.590 0.005
leucine 594.2 0.000
S-(2-methylpropionyl)-
dihydrolipoamide-E
1.188 0.001
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vitro human-relevant models of NAFLD would facilitate the
development of reliable biomarkers of risk, the rapid screen-
ing of novel or existing therapies and the accurate prediction
of toxicity in response to pharmacological compounds,
enabling the development of safe, efficacious and cost-effective
medicines.
Human HLCs possess hepatocyte-like morphology, gene
expression and function [14]. They can be derived from
renewable cell populations at scale, are robust, and are com-
parable to cryopreserved human hepatocytes in terms of
predicting human compound toxicity and model metabolic
differences [29]. Exposure of cells to fatty acids has been
employed to model NAFLD in cell culture systems with var-
ious reports of effects on steatosis, insulin signalling and
activation of apoptosis pathways [6,7,9]. The one previous
report of the use of HLCs to model NAFLD used oleic
acid-induced steatosis and reported perturbation of multiple
metabolic pathways, including activation of the proliferator-
activated receptor (PPAR) pathway [42]. However, the aetiol-
ogy of NAFLD may also include the response to nutritional
excess, hyperinsulinaemia, oxidative stress, adipokine fluctu-
ations, cytokine signalling and the influence of gut-derived
factors [43]. Therefore, more representative models are
required. The high-energy substrates lactate and pyruvate
have been used in combination with the medium chain
fatty acid octanoate and ammonia (LPON) to mimic energy
excess in human hepatoblastoma cell lines [44,45]. This cock-
tail generates hepatic steatosis, impaired mitochondrial
function, increased reactive oxygen species and perturbs
energy metabolites and the cellular proteome, without com-
promising cellular viability [43,44]. Here we show that HLC
exposure to LPO induces an increase in cellular steatosis
and stimulates the expression of multiple genes associated
with NAFLD, demonstrating the importance of HLCs as a
cell-based model of human NAFLD. We also identified tran-
scriptional and metabolic perturbations consistent with
mitochondrial dysfunction, a key feature of NAFLD, with
multiple alterations in TCA cycle metabolism, b-oxidation
and oxidative phosphorylation.Recent studies using both genome-wide and candidate
gene analysis in human liver biopsy specimens and in
animal models have identified alterations in DNA methyl-
ation in NAFLD, suggesting that epigenetic dysregulation
may play a role in its pathogenesis and progression [19–
21]. DNA methylation (5-methylcytosine, 5mC) is important
in the regulation of gene expression and plays a key role in
transcriptional silencing [46]. By contrast, the cytosine modi-
fication 5hmC is enriched over the bodies of expressed genes
as well as at enhancer elements and some promoter regions
[47–49]. While 5hmC appears to function as part of an
active DNA demethylation pathway, catalysed by the TET
enzymes [50], it may also act as a functional DNA methyl-
ation mark. We have suggested that 5hmC patterns may be
useful as an identifier of cell/tissue type and a marker of
cell state and may be a useful tool to identify novel thera-
peutics and assess drug response [22,51]. However, 5hmC
profiles in whole liver from animal models or human
biopsy specimens may be confounded by changes in cell
populations as a consequence of the disease process, because
5hmC patterns are highly cell- and tissue-specific. While the
use of single cell-types overcomes this problem, there are par-
ticular problems with studying 5hmC in vitro: 5hmC is
rapidly lost during somatic cell adaptation to culture, includ-
ing in all tested hepatocyte cell lines [24]. Additionally,
established HCC cell lines are unsuitable because resident
5mC/5hmC changes are a feature of neoplasia that would
confound analyses in these models following interventions
to induce steatosis [25,52]. By contrast, we demonstrate that
HLCs maintain TET expression, have 5hmC profiles consist-
ent with a liver-like epigenome, show 5hmC enrichment
within bodies of induced genes and therefore represent a
transformative resource with which to study epigenetic
changes in human liver disease.
In conclusion, our study shows that HLCs treated with
LPO recapitulate the transcriptional and metabolic dysregula-
tion seen in NAFLD and additionally retain expression of the
TET enzymes and 5hmC. This in vitro model of ‘NAFLD
in a dish’ using a single cell-type will be useful for future
mechanistic and therapeutic studies.
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Figure 4. HLCs retain TET expression and 5hmC and demonstrate genic 5hmC enrichment in activated lipid synthesis and transport genes on LPO exposure. (a) 5hmC
immune slot/blot of mouse liver, HLCs and HepG2 cells. Oligonucleotides of the APC gene promoter were used as controls. (b) qPCR of TET isoform mRNA expression
during differentiation. Values are normalized to internal controls PPIA and B2M and expressed as fold change from undifferentiated ESCs. TET1 and TET3 expression
decreases and TET2 expression increases during hepatic differentiation (*p, 0.05, **p , 0.01, ***p , 0.001 one-way ANOVA with Bonferroni multiple test cor-
rection versus ESCs). (c) Sliding window analysis of hmeDIP-seq displaying 5hmC profiles of HLCs stratified by expression quintile in relation to relative gene length
(mean of two separate hmeDIP-seq experiments). (d ) Sliding window analysis of all genes in control and LPO-treated HLCs (n ¼ 3/group) shows no differences in
global 5hmC levels. Error bars ¼ s.d. (e) Heatmap analysis and unsupervised clustering of change in genic 5hmC specifically over induced genes of lipid synthesis
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